- ►shouxi.net M Battaglia, A Stabilini, E Draghici, B … - Diabetes, 2006 - Am Diabetes Assoc Success in developing novel therapies to recommence self-tolerance in
autoimmunity depends on the induction of T regulatory (Tr) cells. Here, we
report that rapamycin combined with interleukin (IL)-10 efficiently blocks ... Cited by 47 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org M Battaglia, A Stabilini, E Draghici, S … - Diabetes, 2006 - Am Diabetes Assoc Islet transplantation is a cure for type 1 diabetes, but its potential is
limited by the need for constant immunosuppression. One solution to this problem
is the induction of transplantation tolerance mediated by T regulatory ... Cited by 75 - Related articles - BL Direct - All 6 versions
LE Weston, AF Geczy, H Briscoe - Bone Marrow Transplantation, 2005 - nature.com Graft-versus-host disease (GVHD) is a major complication of allogeneic
hematopoietic stem cell transplantation. Pretransplant conditioning regimes
cause release of proinflammatory cytokines that stimulate alloreactive ... Cited by 25 - Related articles - BL Direct - All 3 versions
- ►nih.gov P Monti, M Scirpoli, P Maffi, L Piemonti, A … - Diabetes, 2008 - Am Diabetes Assoc OBJECTIVE—Rapamycin is an immunosuppressive drug currently used to prevent
graft rejection in humans, which is considered permissive for tolerance
induction. Rapamycin allows expansion of both murine and human naturally ... Cited by 9 - Related articles - All 5 versions
- ►pnas.org B Keymeulen, P Gillard, C Mathieu, B … - Proceedings of the National Academy of Sciences, 2006 - National Acad Sciences Islet grafts can induce insulin independence in type 1 diabetic patients, but
their function is variable with only 10% insulin indepence after 5 years. We
investigated whether cultured grafts with defined β cell number help ... Cited by 26 - Related articles - BL Direct - All 10 versions
G Maleux, P Gillard, B Keymeulen, D Pipeleers … - Journal of Vascular and Interventional Radiology, 2005 - Elsevier Between December 2001 and November 2003, 15 patients with C-peptide–negative
type 1 diabetes underwent 31 percutaneous injections for intraportal
implantation of β-cell grafts. Grafts consisted of cultured β-cell ... Cited by 14 - Related articles - BL Direct - All 19 versions
VAL Huurman, R Hilbrands, GGM Pinkse, P … - PLoS ONE, 2008 - pubmedcentral.nih.gov Twenty-one T1D patients received cultured islet cell grafts prepared from
multiple donors and transplanted under anti-thymocyte globulin (ATG) induction
and tacrolimus plus mycophenolate mofetil (MMF) maintenance ... Cited by 13 - Related articles - All 9 versions
M Battaglia, S Gregori, R Bacchetta, MG … - Seminars in Immunology, 2006 - Elsevier Peripheral tolerance is mediated by multiple mechanisms such as anergy and/or
active suppression of effector T cells by T regulatory (Tr) cells. Among the CD4
+ Tr cells, T regulatory type 1 cells (Tr1) have been shown to ... Cited by 84 - Related articles - All 2 versions
- ►hematologylibrary.org MT Lin, B Storer, PJ Martin, LH Tseng, B … - Blood, 2005 - bloodjournal.hematologylibrary.org We have previously shown that the interleukin 10 (IL-10)/-592 * A allele of the
recipient is associated with less severe acute graft-versus-host disease (GVHD)
and a lower risk of nonrelapse mortality after hematopoietic cell ... Cited by 37 - Related articles - BL Direct - All 7 versions
JM Lawson, J Tremble, C Dayan, H Beyan, … - Clinical &# 38; Experimental Immunology, 2008 - ingentaconnect.com Type I diabetes (T1D) is a T cell-mediated autoimmune disease characterized by
loss of tolerance to islet autoantigens, leading to the destruction of
insulin-producing beta cells. Peripheral tolerance to self is maintained in ... Cited by 4 - Related articles - All 2 versions
